HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Use of isosorbide dinitrate and hydralazine in African-Americans with heart failure 9 years after the African-American Heart Failure Trial.

Abstract
The 2013 American College of Cardiology Foundation/American Heart Association guidelines recommend combined isosorbide dinitrate (ISDN) and hydralazine to reduce mortality and morbidity for African-Americans with symptomatic heart failure (HF) and reduced ejection fraction, currently receiving optimal medical therapy (class I, level A). Nitrates can alleviate HF symptoms, but continuous use is limited by tolerance. Hydralazine may mitigate nitrate tolerance, and the ISDN-hydralazine combination in the Vasodilators in Heart Failure Trial (V-HeFT) I improved survival and exercise tolerance in men with dilated cardiomyopathy or HF with reduced ejection fraction, most notably in self-identified black participants. In the subsequent V-HeFT II, survival was greater with enalapril than with ISDN-hydralazine in the overall cohort, but mortality rate was similar in the enalapril and ISDN-hydralazine groups in the self-identified black patients. Consequently, in the African-American Heart Failure Trial (A-HeFT) in self-identified black patients with symptomatic HF, adding a fixed-dose combination ISDN-hydralazine to modern guideline-based care improved outcomes versus placebo, including all-cause mortality, and led to early trial termination. Hypertension underlies HF, especially in African-Americans; the A-HeFT and its substudies demonstrated not only improvements in echocardiographic parameters, morbidity, and mortality but also a decrease in hospitalizations, potentially affecting burgeoning HF health-care costs. Genetic characteristics may, therefore, determine response to ISDN-hydralazine, and the Genetic Risk Assessment in Heart Failure substudy demonstrated important hypothesis-generating pharmacogenetic data.
AuthorsKeith Copelin Ferdinand, Uri Elkayam, Donna Mancini, Elizabeth Ofili, Ileana Piña, Inder Anand, Arthur Michael Feldman, Dennis McNamara, Christopher Leggett
JournalThe American journal of cardiology (Am J Cardiol) Vol. 114 Issue 1 Pg. 151-9 (Jul 01 2014) ISSN: 1879-1913 [Electronic] United States
PMID24846808 (Publication Type: Journal Article, Review)
CopyrightCopyright © 2014 Elsevier Inc. All rights reserved.
Chemical References
  • Drug Combinations
  • isosorbide-hydralazine combination
  • Hydralazine
  • Isosorbide Dinitrate
Topics
  • Black or African American
  • Drug Combinations
  • Heart Failure (drug therapy, mortality)
  • Humans
  • Hydralazine (therapeutic use)
  • Isosorbide Dinitrate (therapeutic use)
  • Practice Guidelines as Topic

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: